Japanese

 

Department of Life Science and Biotechnology

Realizing a healthy, active, aged society and creating a sustainable society

A society in which people live a long life in good health and at ease, and a sustainable society with reduced environmental load is desired. We are contributing to life innovation by developing new technologies to evaluate health and to promote drug discovery, as well as to maintain, improve, and recover health according to individual conditions. We are also contributing to green innovation by developing technologies to reduce environmental loads using bioprocesses.

 
Figure
 

New Research Results

Enhancement of Ozone Tolerance by Adjusting Stomatal Aperture on Leaf Surface

AIST discovered that expressing chimeric repressors of the transcription factors that control the development of chloroplasts in plants (transcription factors GLK1 and GLK2) significantly improves resistance to ozone, which is an atmospheric pollutant. In plants which were made to express the chimeric repressors of these transcription factors, the researchers found that stomata close slightly, and the transcription factors GLK1 and GLK2 affect factors relating to the stomatal movements. It is expected that if stomatal aperture can be properly adjusted using these transcription factors, it would contribute to the development of crops that are tolerant to environmental stress, such as atmospheric pollution and drought.

 GLK1SRDX transformed Arabidopsis thaliana is tolerant to high concentrations of ozone. figure

GLK1SRDX transformed Arabidopsis thaliana is tolerant to high concentrations of ozone.

Development of Technology to Evaluate the Differentiation Ability of Human Mesenchymal Stem Cells

AIST has developed a technology to evaluate the differentiation ability of human mesenchymal stem cells using α2-6 sialic acid-binding lectins, in collaboration with the National Center for Child Health and Development and the Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology. Human mesenchymal stem cells have garnered attention as a cell source for regenerative medicine. However, there was no method for evaluating their differentiation ability, which posed a problem in applying them to regenerative medicine. The developed technology is expected to contribute to the improved effectiveness of regenerative medicine using human mesenchymal stem cells. Wako Pure Chemical Industries plans to commercialize this technology within one year.

The technology for evaluating the differentiation ability of human mesenchymal stem cells figure

The technology for evaluating the differentiation ability of human mesenchymal stem cells


Research Unit

▲ ページトップへ